{"protocolSection": {"identificationModule": {"nctId": "NCT00585546", "nctIdAliases": ["NCT00701116"], "orgStudyIdInfo": {"id": "HARPS"}, "organization": {"fullName": "University of Michigan", "class": "OTHER"}, "briefTitle": "Harefield Recovery Protocol Study for Patients With Refractory Chronic Heart Failure", "officialTitle": "Harefield Recovery Protocol Study (HARPS): A Nonrandomized, Open Label, Multicenter Evaluation of Potential Recovery of Heart Function in Patients With Refractory Chronic Heart Failure by Treatment With Combination of Left Ventricular Assist Device (LVAD), Drugs to Induce Maximal Reverse Remodeling and the Beta-2 Adrenergic Receptor Agonist Clenbuterol.", "acronym": "HARPS"}, "statusModule": {"statusVerifiedDate": "2017-05", "overallStatus": "TERMINATED", "whyStopped": "No longer could obtain clenbuterol", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-07"}, "primaryCompletionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2010-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-12-26", "studyFirstSubmitQcDate": "2007-12-26", "studyFirstPostDateStruct": {"date": "2008-01-03", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2017-03-25", "resultsFirstSubmitQcDate": "2017-05-16", "resultsFirstPostDateStruct": {"date": "2017-12-15", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2017-05-16", "lastUpdatePostDateStruct": {"date": "2017-12-15", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR_INVESTIGATOR", "investigatorFullName": "Francis D. Pagani", "investigatorTitle": "Professor of Cardiac Surgery", "investigatorAffiliation": "University of Michigan"}, "leadSponsor": {"name": "Francis D. Pagani", "class": "OTHER"}, "collaborators": [{"name": "Georgetown University", "class": "OTHER"}, {"name": "Montefiore Medical Center", "class": "OTHER"}, {"name": "Northwestern University", "class": "OTHER"}, {"name": "Ohio State University", "class": "OTHER"}, {"name": "Texas Heart Institute", "class": "OTHER"}, {"name": "University of Minnesota", "class": "OTHER"}, {"name": "University of Pennsylvania", "class": "OTHER"}, {"name": "Thoratec Corporation", "class": "INDUSTRY"}]}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to evaluate whether patients with chronic heart failure not due to coronary artery disease who require use of a left ventricular assist device (LVAD) for refractory heart failure can recover sufficient heart function to allow the pump to be explanted. The study aims to avoid the need for transplantation in these patients by using standard heart failure medications to reduce the size of the left ventricle and then using the investigational drug, clenbuterol, to further improve left ventricular function.", "detailedDescription": "The hypothesis of this study is that patients with dilated nonischemic cardiomyopathy who require support with an implanted left ventricular assist device (LVAD) for chronic refractory heart failure can, with a specific two-staged medical regimen designed to enhance maximal reverse remodeling (an angiotensin converting enzyme inhibitor, beta blocker, angiotensin receptor blocker, aldosterone antagonist and digoxin \\[stage 1\\]) and prevent/reverse myocardial atrophy (the \u03b22 agonist clenbuterol \\[stage 2\\]), recover adequate left ventricular systolic function to allow LVAD explantation and subsequent intermediate-term survival without need for mechanical circulatory support or heart transplantation.\n\nWithin one year of this study's start, a new LVAD became the standard of care for implantation, so the study device became an inferior standard of care shortly thereafter. By 2012 the trial was stopped for futility in enrollment. Thus, certain original outcomes have been deleted, specifically because there was only a single subject explanted, multivariate analysis for sustainability of reverse remodeling following LVAD explantation and predictors of recovery of left ventricular function/remodeling and of LVAD removal could not be done.\n\nSimilarly, and for lack of funding, biobank components were not collected; therefore no data exists to present biochemical, structural, cellular and molecular changes in the myocardium resulting from the HARPS protocol interventions, changes in systemic inflammation, circulating progenitor cells and growth factors, or DEXA scan based data: changes in body mass, lean muscle mass, muscle strength and maximal and submaximal exercise capacity. All remaining outcome measures have been edited to more precisely show the outcome measures intended."}, "conditionsModule": {"conditions": ["Heart Failure", "Dilated Cardiomyopathy"], "keywords": ["heart failure", "dilated cardiomyopathy", "heart assist device", "clenbuterol", "adrenergic beta agonists", "heart transplantation"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "NA", "interventionModel": "SINGLE_GROUP", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 18, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "LVAD and Clenbuterol", "type": "EXPERIMENTAL", "interventionNames": ["Drug: clenbuterol"]}], "interventions": [{"type": "DRUG", "name": "clenbuterol", "description": "Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.", "armGroupLabels": ["LVAD and Clenbuterol"], "otherNames": ["Spiropent"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Percent of Subjects Who Experience LVAD Removal and Subsequent Freedom From Mechanical Circulatory Support or Heart Transplantation for 1-year After Explantation", "timeFrame": "One year after LVAD explant or until transplant or death (if not explanted)"}], "secondaryOutcomes": [{"measure": "The Number of Evaluable Subjects Meeting Explant Criteria and Subsequently Explanted", "timeFrame": "Maximum 12 months after LVAD implantation"}, {"measure": "Number of Subjects Who Received Maximum Target Dose of Clenbuterol", "timeFrame": "Up to 16 months after LVAD implantation (12 months after beginning clenbuterol)"}, {"measure": "Time to Device Explant for Subjects Meeting Explant Criteria Defined in the Protocol", "description": "Time from LVAD placement to explant for the single participant who achieved explant", "timeFrame": "Time to explant (but not to be followed for more than 16 months)"}, {"measure": "Absolute Change in Left Ventricular Ejection Fraction From Explant to 18 Months Following Device Explant", "timeFrame": "18 months after explantation"}, {"measure": "Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Implant", "timeFrame": "Up to 8 weeks after LVAD implantation"}, {"measure": "Mean Change in EuroQoL Visual Analog Scale (EQ5D-VAS) From Baseline to 6 Months and 1 Year Following Device Implant", "description": "Scale 0 - 100 where 0 is worst possible health state and 100 is perfect health.", "timeFrame": "1 year following LVAD implantation"}, {"measure": "Mean Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to 6 Months", "description": "Scale 0 - 105 (0- 5 on 21 items) where 0 means heart failure has not limited daily life at all and high scores mean that daily functions are greatly limited.", "timeFrame": "6 months following LVAD implantation"}, {"measure": "Mean Change in Left Ventricular Ejection Fraction From Device Implant to Completion of Clenbuterol Therapy", "timeFrame": "up to 16 months, variable based on length of time receiveing clenbuterol"}, {"measure": "Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Clenbuterol", "timeFrame": "baseline to week 8 post clenbuterol"}, {"measure": "Mean Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to 1 Year Following Device Implant", "description": "Scale 0 - 105 (0- 5 on 21 items) where 0 means heart failure has not limited daily life at all and high scores mean that daily functions are greatly limited.", "timeFrame": "1 year"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nPatients with refractory symptomatic heart failure (NYHA Class IV, or Stage D) due to dilated, non-ischemic cardiomyopathy who meet the following criteria:\n\n* Severe clinical heart failure with associated haemodynamic compromise resistant to intensive medical therapy and requiring LVAD implantation\n* Duration of heart failure symptoms to be \u2265 12 months prior to LVAD implant\n* Documentation of LVEF \u2264 40% at least 1 year prior to LVAD implantation\n* LVEF \u2264 30% and cardiomegaly at the time of LVAD implantation as documented by radionuclide or contrast ventriculography or by echocardiography\n* Nonischemic etiology confirmed by coronary angiography within two years of enrollment\n* Listed for heart transplantation or plan to list for heart transplantation pending successful LVAD implantation in one of the participating centers, as per usual transplant listing policy at each participating center\n* \\>= 18 years of age\n* Body surface area \\>= 1.5 m2\n* Have an implantable defibrillator in place or a commitment to implant an ICD prior to hospital discharge\n* Have undergone insertion within prior 2 weeks or will be inserted with a Heartmate XVE LVAD with use of antimicrobial prophylaxis and drive line restraining belt\n\nExclusion Criteria:\n\n* Not a heart transplant candidate\n* Evidence of active acute myocarditis\n* Pulmonary Vascular Resistance \\> 6 Wood Units\n* History of previous CVA resulting in significant fixed motor deficit limiting ability to perform exercise testing\n* Previous prosthetic replacement of aortic and/or mitral valve(s)\n* Hypertrophic obstructive cardiomyopathy\n* LVIDD \\< 5 cm by surface echocardiogram (restrictive cardiomyopathy)\n* Irreversible multi-organ failure\n* Underlying bleeding disorder, or platelet count \\< 75,000, INR \\> 2.5 (without Coumadin), or Hgb \\< 8.0.\n* Pregnant or lactating women or unwilling to utilize two reliable methods of birth control for women of childbearing age\n* Receipt of other investigational drug therapy during LVAD support", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Leslie W. Miller, MD", "affiliation": "Georgetown University", "role": "PRINCIPAL_INVESTIGATOR"}, {"name": "Keith D. Aaronson, MD, MS", "affiliation": "University of Michigan", "role": "STUDY_DIRECTOR"}, {"name": "Francis D. Pagani, MD, PhD", "affiliation": "University of Michigan", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Georgetown Hospital", "city": "Washington, D.C.", "state": "District of Columbia", "zip": "20010", "country": "United States", "geoPoint": {"lat": 38.89511, "lon": -77.03637}}, {"facility": "Northwestern University", "city": "Chicago", "state": "Illinois", "zip": "60611", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "University of Michigan Health System", "city": "Ann Arbor", "state": "Michigan", "zip": "48109", "country": "United States", "geoPoint": {"lat": 42.27756, "lon": -83.74088}}, {"facility": "Montefiore Medical Center", "city": "The Bronx", "state": "New York", "zip": "10467", "country": "United States", "geoPoint": {"lat": 40.84985, "lon": -73.86641}}, {"facility": "Ohio State University", "city": "Columbus", "state": "Ohio", "zip": "43210", "country": "United States", "geoPoint": {"lat": 39.96118, "lon": -82.99879}}, {"facility": "University of Pennsylvania", "city": "Philadelphia", "state": "Pennsylvania", "zip": "19014", "country": "United States", "geoPoint": {"lat": 39.95233, "lon": -75.16379}}, {"facility": "Texas Heart Institute", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}]}, "referencesModule": {"references": [{"pmid": "17079761", "type": "BACKGROUND", "citation": "Birks EJ, Tansley PD, Hardy J, George RS, Bowles CT, Burke M, Banner NR, Khaghani A, Yacoub MH. Left ventricular assist device and drug therapy for the reversal of heart failure. N Engl J Med. 2006 Nov 2;355(18):1873-84. doi: 10.1056/NEJMoa053063."}]}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Of 19 consented, 1 was a screen fail and did not enter the study protocol.", "groups": [{"id": "FG000", "title": "LVAD and (Intended) Clenbuterol", "description": "Participants, all of whom received LVAD implantation, were to begin clenbuterol treatment 12 weeks after their implantation.\n\nClenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "periods": [{"title": "LVAD Implantation Required for 4 Months", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "5"}]}]}, {"title": "Clenbuterol Treatment - up to 12 Months", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "9"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}]}], "dropWithdraws": [{"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEDIAN", "dispersionType": "INTER_QUARTILE_RANGE", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "57", "lowerLimit": "54", "upperLimit": "62"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "2"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "16"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "United States", "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Percent of Subjects Who Experience LVAD Removal and Subsequent Freedom From Mechanical Circulatory Support or Heart Transplantation for 1-year After Explantation", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "percentage of participants", "timeFrame": "One year after LVAD explant or until transplant or death (if not explanted)", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.6"}]}]}]}, {"type": "SECONDARY", "title": "The Number of Evaluable Subjects Meeting Explant Criteria and Subsequently Explanted", "populationDescription": "Because only 13 began Clenbuterol, only 13 are \"evaluable\" for this purpose.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Maximum 12 months after LVAD implantation", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "1"}]}]}]}, {"type": "SECONDARY", "title": "Number of Subjects Who Received Maximum Target Dose of Clenbuterol", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to 16 months after LVAD implantation (12 months after beginning clenbuterol)", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "13"}]}]}]}, {"type": "SECONDARY", "title": "Time to Device Explant for Subjects Meeting Explant Criteria Defined in the Protocol", "description": "Time from LVAD placement to explant for the single participant who achieved explant", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "weeks", "timeFrame": "Time to explant (but not to be followed for more than 16 months)", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Change in Left Ventricular Ejection Fraction From Explant to 18 Months Following Device Explant", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "absolute change in ejection fraction", "timeFrame": "18 months after explantation", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "1"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-.09"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Implant", "populationDescription": "Because data only is available for 15 participants for 8 week post implant AST value, it has a different participants analyzed value", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "Up to 8 weeks after LVAD implantation", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "classes": [{"title": "Creatinine", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.2", "spread": "15.2"}]}]}, {"title": "aspartate transaminase (AST)", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "15"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "25", "spread": "19.7"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change in EuroQoL Visual Analog Scale (EQ5D-VAS) From Baseline to 6 Months and 1 Year Following Device Implant", "description": "Scale 0 - 100 where 0 is worst possible health state and 100 is perfect health.", "populationDescription": "While baseline data was available for 13 participants at baseline, (start of clenbuterol), different numbers of participants provided evaluable data At six months post implant and 12 months, so the mean changes are based on the actual population that provided both data points as listed below", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "1 year following LVAD implantation", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "13"}]}], "classes": [{"title": "6 months post implant", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "7"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "46", "spread": "35"}]}]}, {"title": "12 months post implant", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "12"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "51", "spread": "30"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to 6 Months", "description": "Scale 0 - 105 (0- 5 on 21 items) where 0 means heart failure has not limited daily life at all and high scores mean that daily functions are greatly limited.", "populationDescription": "Only 11 participants provided usable data at the six month time point.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "6 months following LVAD implantation", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "11"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "28.3", "spread": "19.7"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change in Left Ventricular Ejection Fraction From Device Implant to Completion of Clenbuterol Therapy", "populationDescription": "data is available for 9 evaluable subjects at end of clenbuterol", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ejection fraction", "timeFrame": "up to 16 months, variable based on length of time receiveing clenbuterol", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.16", "spread": ".10"}]}]}]}, {"type": "SECONDARY", "title": "Absolute Percent Change in Serum Creatinine and Aspartate Transaminase (AST) From Baseline to Week 8 Post Clenbuterol", "populationDescription": "baseline data is based on 19 participants, but different subsequent data collections had different numbers of evaluable subjects listed below", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "percent change", "timeFrame": "baseline to week 8 post clenbuterol", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "19"}]}], "classes": [{"title": "creatinine from baseline to week 8 of clenbuterol", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "10"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "-15.8", "spread": "13.3"}]}]}, {"title": "AST from baseline to week 8 on clenbuterol", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "9"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "15.6", "spread": "14.3"}]}]}]}, {"type": "SECONDARY", "title": "Mean Change in Minnesota Living With Heart Failure Questionnaire (MLHFQ) From Baseline to 1 Year Following Device Implant", "description": "Scale 0 - 105 (0- 5 on 21 items) where 0 means heart failure has not limited daily life at all and high scores mean that daily functions are greatly limited.", "populationDescription": "Data is not available for Minnesota Living with Heart Failure Questionnaire at the 12 month time point.", "reportingStatus": "POSTED", "timeFrame": "1 year", "groups": [{"id": "OG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "0", "timeFrame": "Adverse event data was collected for approximately 24 months or up to transplant, death, or explant", "eventGroups": [{"id": "EG000", "title": "LVAD and Clenbuterol", "description": "clenbuterol: Clenbuterol 20 mcg tablets uptitrated from 20 mcg PO TID to a maximally tolerated dose not to exceed 700 mcg PO TID. Patients will then be switched to the equivalent dose of clenbuterol liquid 59 mcg/ml PO TID. Clenbuterol will be administered for a minimum of 3 months and a maximum of 12 months.", "deathsNumAffected": 1, "deathsNumAtRisk": 18, "seriousNumAffected": 13, "seriousNumAtRisk": 18, "otherNumAffected": 11, "otherNumAtRisk": 18}], "seriousEvents": [{"term": "Abdominal Perforation Requiring Re-Operation", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Anemia, Pancytopenia", "organSystem": "Blood and lymphatic system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "AV Endocarditis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Bleeding", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 18}]}, {"term": "Cardiac arrhythmia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 18}]}, {"term": "Cardiopulmonary Arrest", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Dehydration", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Device malfunction", "organSystem": "Product Issues", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 18}]}, {"term": "Fever", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Hemoptysis", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "History Afib/Flutter since XVE Implant", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 18}]}, {"term": "Intermittent Fever, Pain, Leukocytosis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Left Atrial Thrombus", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Left Pleural Effusion", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Left Sided Pain Radiating to Axilla", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Left sided pneumothorax - Left Pleural CT inserted", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Nausea and Vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Neurological event", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 18}]}, {"term": "Renal dysfunction", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Retropericardial Hematoma", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Shortness of Breath", "organSystem": "Respiratory, thoracic and mediastinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Viral Syndrome", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Pericardial fluid collection", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Heart Failure", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}], "otherEvents": [{"term": "Abdominal Pain", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Bleeding", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Cardiac arrhythmia", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Chest Pain", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Elevated White Blood Cell/Leukocytosis", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Hyperkalemia", "organSystem": "Renal and urinary disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Hypertension", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 18}]}, {"term": "Implantable Cardioverter Defibrillator (ICD) Discharge", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Infection", "organSystem": "Infections and infestations", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 18}]}, {"term": "Muscle Pain", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Myalgia", "organSystem": "Musculoskeletal and connective tissue disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Neurological", "organSystem": "Nervous system disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 18}]}, {"term": "Psychiatric episode", "organSystem": "Psychiatric disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Severe Muscle Spasms", "organSystem": "Injury, poisoning and procedural complications", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Sinus Tachycardia Leading to ICD Shocks", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Hypotension", "organSystem": "Cardiac disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}, {"term": "Blood Bowel Movement", "organSystem": "Gastrointestinal disorders", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 18}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "Because a new standard of care was developed during the start of the trial, the trial was stopped for futility in enrollment. The public should exercise great caution in drawing conclusions from such a small sample size."}, "certainAgreement": {"piSponsorEmployee": true}, "pointOfContact": {"title": "Francis Pagani", "organization": "University of Michigan", "email": "fpagani@med.umich.edu", "phone": "734 647-2894"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}, {"id": "D000009202", "term": "Cardiomyopathies"}, {"id": "D000002311", "term": "Cardiomyopathy, Dilated"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}, {"id": "D000006332", "term": "Cardiomegaly"}, {"id": "D000083083", "term": "Laminopathies"}, {"id": "D000030342", "term": "Genetic Diseases, Inborn"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M12154", "name": "Cardiomyopathies", "asFound": "Cardiomyopathy", "relevance": "HIGH"}, {"id": "M5567", "name": "Cardiomyopathy, Dilated", "asFound": "Dilated Cardiomyopathy", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "M9420", "name": "Cardiomegaly", "relevance": "LOW"}, {"id": "M2392", "name": "Laminopathies", "relevance": "LOW"}, {"id": "M23686", "name": "Genetic Diseases, Inborn", "relevance": "LOW"}, {"id": "T1303", "name": "Chronic Graft Versus Host Disease", "relevance": "LOW"}, {"id": "T1876", "name": "Dilated Cardiomyopathy", "asFound": "Dilated Cardiomyopathy", "relevance": "HIGH"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC16", "name": "Diseases and Abnormalities at or Before Birth"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000002976", "term": "Clenbuterol"}], "ancestors": [{"id": "D000000318", "term": "Adrenergic beta-Agonists"}, {"id": "D000000322", "term": "Adrenergic Agonists"}, {"id": "D000018663", "term": "Adrenergic Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000001993", "term": "Bronchodilator Agents"}, {"id": "D000001337", "term": "Autonomic Agents"}, {"id": "D000018373", "term": "Peripheral Nervous System Agents"}, {"id": "D000018927", "term": "Anti-Asthmatic Agents"}, {"id": "D000019141", "term": "Respiratory System Agents"}, {"id": "D000013566", "term": "Sympathomimetics"}], "browseLeaves": [{"id": "M20746", "name": "Adrenergic Agents", "relevance": "LOW"}, {"id": "M6210", "name": "Clenbuterol", "asFound": "Adhesion molecule", "relevance": "HIGH"}, {"id": "M3673", "name": "Adrenergic Agonists", "relevance": "LOW"}, {"id": "M3670", "name": "Adrenergic beta-Agonists", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M5269", "name": "Bronchodilator Agents", "relevance": "LOW"}, {"id": "M20963", "name": "Anti-Asthmatic Agents", "relevance": "LOW"}, {"id": "M21137", "name": "Respiratory System Agents", "relevance": "LOW"}, {"id": "M16345", "name": "Sympathomimetics", "relevance": "LOW"}], "browseBranches": [{"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Resp", "name": "Respiratory System Agents"}]}}, "hasResults": true}